Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation

Bentley, Robert, Hardy, Lewis J, Scott, Laura J, Sharma, Parveen ORCID: 0000-0002-5534-2417, Philippou, Helen and Lip, Gregory YH (2021) Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation. Expert Opinion on Investigational Drugs, 30 (10). pp. 1057-1069.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1080/13543784.2021.1897786

Abstract

<h4>Introduction</h4>Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia globally and is associated with ischemic stroke and heart failure. Patients with atrial fibrillation are typically prescribed long-term anticoagulants in the form of either vitamin K antagonists or non-vitamin K antagonist oral anticoagulants; however, both carry a potential risk of adverse bleeding.<h4>Areas covered</h4>This paper sheds light on emerging anticoagulant agents which target clotting factors XI and XII, or their activated forms - XIa and XIIa, respectively, within the intrinsic coagulation pathway. The authors examined data available on PubMed, Scopus, and the clinical trials registry of the United States National Library of Medicine (www.clinicaltrials.gov).<h4>Expert opinion</h4>Therapies targeting factors XI or XII can yield anticoagulant efficacy with the potential to reduce adverse bleeding. Advantages for targeting factor XI or XII include a wider therapeutic window and reduced bleeding. Long-term follow-up studies and a greater understanding of the safety and efficacy are required. Atrial fibrillation is a chronic disease and therefore the development of oral formulations is key.

Item Type:	Article
Uncontrolled Keywords:	Anticoagulant, antibody, antisense oligonucleotide, atrial fibrillation, clotting factor, intrinsic pathway, clinical trial, novel, small molecule, stroke, thromboembolism, fxi, fxii, therapeutics
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User:	Symplectic Admin
Date Deposited:	17 Jun 2021 07:47
Last Modified:	18 Jan 2023 22:46
DOI:	10.1080/13543784.2021.1897786
Open Access URL:	https://doi.org/10.1080/13543784.2021.1897786
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3123286